Moonlake Immunotherapeutics Begins Phase 3 VELA Program Of The Nanobody Sonelokimab In Patients With Moderate-To-Severe Hidradenitis Suppurativa; Topline Primary Endpoint Readout At Week 16, Together With Data On Other Endpoints, Is Expected As Of Mid-2025
Portfolio Pulse from Benzinga Newsdesk
MoonLake Immunotherapeutics has initiated the Phase 3 VELA program for its Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa. The program will use the HiSCR75 clinical response level as the primary endpoint, with topline results expected by mid-2025.
May 16, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MoonLake Immunotherapeutics has started the Phase 3 VELA program for sonelokimab in patients with moderate-to-severe hidradenitis suppurativa. The program will use the HiSCR75 clinical response level as the primary endpoint, with topline results expected by mid-2025.
The initiation of a Phase 3 trial is a significant milestone for any biotech company, indicating progress in the development of a potentially marketable drug. The use of a higher clinical response level (HiSCR75) as the primary endpoint and the expected topline results by mid-2025 are positive indicators for the company's future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100